Epidermal Growth Factor Receptor
Mostrando 1-12 de 1081 artigos, teses e dissertações.
-
1. Scanning electron microscopy of panitumumab-induced eyelash and hair alterations - Pili canaliculi
Abstract Panitumumab is a monoclonal antibody against the epidermal growth factor receptor used in metastatic colorectal cancer; in addition to tumor cells, it acts on epidermal keratinocytes and on the outer root sheath and presents skin toxicity in up to 90% of cases. A scanning electron microscope was used to examine the eyelashes and hairs of a 65-year-o
Anais Brasileiros de Dermatologia. Publicado em: 2022
-
2. Comparative analysis of the histopathological and epidemiological profile of ductal and lobular breast carcinomas diagnosed at the Hospital de Clínicas da Universidade Federal do Paraná during the period 2008-2013
RESUMO Introdução: O câncer da mama éa segunda causa de morte por câncer entre as mulheres em todo o mundo, e estuáis epidemiológicos podem auxiliar no entendimento dos seus mecanismos. Objetivos: Realizar um levantamento do número de casos dos carcinomas da mama diagnosticados em um período de seis anos. Método: Foi comparado com a literatura o
J. Bras. Patol. Med. Lab.. Publicado em: 09/05/2019
-
3. Development of radioimmunoconjugate for diagnosis and management of head-and-neck subclinical cancer and colorectal carcinoma
ABSTRACT Scientific innovations in diagnostic methods are important drivers of cancer control and prevention. Noninvasive imaging of the epidermal growth factor receptor (EGFR) in head-and-neck squamous, cell carcinoma and colorectal cancer could be valuable to select patients for EGFR-targeted therapy, as well as to monitor the efficacy and occurrence of re
Braz. J. Pharm. Sci.. Publicado em: 09/04/2018
-
4. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer
Cervical cancer is a public health problem and the molecular mechanisms underlying radioresistance are still poorly understood. Here, we evaluated the modulation of key molecules involved in cell proliferation, cell cycle and DNA repair in cervical cancer cell lines (CASKI and C33A) and in malignant tissues biopsied from 10 patients before and after radiothe
Braz J Med Biol Res. Publicado em: 13/11/2017
-
5. O papel das mutações IDH1/2 na patogênese dos glioblastomas secundários
RESUMO Astrocitoma difuso e glioblastoma (GBM) constituem um grupo de neoplasias astrocíticas infiltrantes difusas, que mais comumente surgem nos hemisférios cerebrais de adultos. A prevalência da transformação maligna de astrocitoma difuso para astrocitoma anaplásico e GBM varia de 40% a 75% dos casos em diferentes séries. Distintas anormalidades gen
J. Bras. Patol. Med. Lab.. Publicado em: 2017-10
-
6. Blood levels of pro-inflammatory and anti-inflammatory cytokines during an oral glucose tolerance test in patients with symptoms suggesting reactive hypoglycemia
We evaluated the impact of postprandial glycemia on blood levels of pro-inflammatory and anti-inflammatory cytokines during an oral glucose tolerance test in non-diabetic patients with symptoms suggesting reactive hypoglycemia. Eleven patients with clinical symptoms suggesting reactive hypoglycemia received an oral glucose solution (75 g) Blood was collected
Braz J Med Biol Res. Publicado em: 11/07/2016
-
7. Cell cycle synchronization and BrdU incorporation as a tool to study the possible selective elimination of ErbB1 gene in the micronuclei in A549 cells
Lung cancer often exhibits molecular changes, such as the overexpression of the ErbB1 gene that encodes epidermal growth factor receptor (EGFR). ErbB1 amplification and mutation are associated with tumor aggressiveness and low response to therapy. The aim of the present study was to design a schedule to synchronize the cell cycle of A549 cell line (a non-sma
Braz J Med Biol Res. Publicado em: 06/03/2015
-
8. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced stages, and available systemic therapies are mostly palliative. The probing of the NSCLC kinome has identified numerous nonoverlapping driver genomic events, including epidermal gro
Braz J Med Biol Res. Publicado em: 05/09/2014
-
9. A expressão imuno-histoquímica de Ki67, EGFR E TRKC e sua correlação com fatores prognósticos em meduloblastomas
Introdução: O meduloblastoma é o tumor maligno do cerebelo com prognóstico reservado. Seu tratamento baseia-se somente em critérios clínicos, como os grupos de risco que levam em consideração apenas idade, extensão de ressecção, recidiva e metástase. Objetivo: Avaliar uma possível relação entre a imunoexpressão de biomarcadores (Ki67, rece
J. Bras. Patol. Med. Lab.. Publicado em: 2014-08
-
10. Avaliação da expressão imuno-histoquímica do HER2 em câncer gástrico em uma coorte de 118 pacientes brasileiros
INTRODUÇÃO: Estudos recentes indicam o papel do human epidermal growth factor receptor type 2 (HER2) no desenvolvimento de vários tipos de câncer, incluindo o gástrico. Sua superexpressão correlaciona-se com pior prognóstico e maior agressividade dessa neoplasia. OBJETIVOS: Identificar e avaliar a expressão imuno-histoquímica de HER2 no câncer gás
J. Bras. Patol. Med. Lab.. Publicado em: 2013-10
-
11. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ
OBJECTIVES: Biological markers that predict the development of invasive breast cancer are needed to improve personalized therapy for patients diagnosed with ductal carcinoma in situ. We investigated the role of basal cytokeratin 5/6 in the risk of invasion in breast ductal carcinoma in situ. METHODS: We constructed tissue microarrays using 236 ductal carc
Clinics. Publicado em: 2013-05
-
12. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast
OBJECTIVE: To determine the frequency of the immunohistochemical profiles of a series of high-grade ductal carcinoma in situ of the breast. METHODS: One hundred and twenty-one cases of high-grade ductal carcinoma in situ, pure or associated with invasive mammary carcinoma, were identified from 2003 to 2008 and examined with immunohistochemistry for estrog
Clinics. Publicado em: 2013-05